nodes	percent_of_prediction	percent_of_DWPC	metapath
Ondansetron—HTR4—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0399	0.0596	CbGpPWpGaD
Ondansetron—HTR4—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0328	0.0491	CbGpPWpGaD
Ondansetron—HTR4—brain—Gilles de la Tourette syndrome	0.0304	0.0917	CbGeAlD
Ondansetron—SLC47A2—nervous system—Gilles de la Tourette syndrome	0.0301	0.0909	CbGeAlD
Ondansetron—SLC47A2—central nervous system—Gilles de la Tourette syndrome	0.029	0.0875	CbGeAlD
Ondansetron—HTR4—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.028	0.0419	CbGpPWpGaD
Ondansetron—HTR4—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0272	0.0407	CbGpPWpGaD
Ondansetron—HTR4—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0253	0.0379	CbGpPWpGaD
Ondansetron—HTR4—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0235	0.0352	CbGpPWpGaD
Ondansetron—SLC47A2—brain—Gilles de la Tourette syndrome	0.023	0.0695	CbGeAlD
Ondansetron—HTR4—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.0229	0.0342	CbGpPWpGaD
Ondansetron—HTR4—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0213	0.0318	CbGpPWpGaD
Ondansetron—HTR4—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.0177	0.0265	CbGpPWpGaD
Ondansetron—HTR1B—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0167	0.0249	CbGpPWpGaD
Ondansetron—SLC47A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.0163	0.0244	CbGpPWpGaD
Ondansetron—HTR4—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.0149	0.0223	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0137	0.0205	CbGpPWpGaD
Ondansetron—HTR1A—Serotonin receptors—HTR2A—Gilles de la Tourette syndrome	0.0127	0.019	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0121	0.0181	CbGpPWpGaD
Ondansetron—OPRM1—midbrain—Gilles de la Tourette syndrome	0.012	0.0361	CbGeAlD
Ondansetron—HTR1B—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.0117	0.0175	CbGpPWpGaD
Ondansetron—HTR1B—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0114	0.017	CbGpPWpGaD
Ondansetron—HTR1B—midbrain—Gilles de la Tourette syndrome	0.0109	0.0331	CbGeAlD
Ondansetron—HTR3A—nervous system—Gilles de la Tourette syndrome	0.0107	0.0324	CbGeAlD
Ondansetron—HTR1B—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.0106	0.0158	CbGpPWpGaD
Ondansetron—SLC47A1—nervous system—Gilles de la Tourette syndrome	0.0105	0.0318	CbGeAlD
Ondansetron—SLC47A1—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.0105	0.0157	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0105	0.0156	CbGpPWpGaD
Ondansetron—HTR3A—central nervous system—Gilles de la Tourette syndrome	0.0103	0.0312	CbGeAlD
Ondansetron—SLC47A1—central nervous system—Gilles de la Tourette syndrome	0.0101	0.0306	CbGeAlD
Ondansetron—HTR1B—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00984	0.0147	CbGpPWpGaD
Ondansetron—OPRM1—nervous system—Gilles de la Tourette syndrome	0.00983	0.0297	CbGeAlD
Ondansetron—HTR1B—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00955	0.0143	CbGpPWpGaD
Ondansetron—OPRM1—central nervous system—Gilles de la Tourette syndrome	0.00947	0.0286	CbGeAlD
Ondansetron—HTR1B—nervous system—Gilles de la Tourette syndrome	0.009	0.0272	CbGeAlD
Ondansetron—HTR1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00892	0.0133	CbGpPWpGaD
Ondansetron—HTR1B—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.0089	0.0133	CbGpPWpGaD
Ondansetron—HTR1A—midbrain—Gilles de la Tourette syndrome	0.00883	0.0267	CbGeAlD
Ondansetron—HTR1B—central nervous system—Gilles de la Tourette syndrome	0.00866	0.0262	CbGeAlD
Ondansetron—HTR1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00866	0.0129	CbGpPWpGaD
Ondansetron—HTR3A—brain—Gilles de la Tourette syndrome	0.0082	0.0248	CbGeAlD
Ondansetron—HTR1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00806	0.0121	CbGpPWpGaD
Ondansetron—SLC47A1—brain—Gilles de la Tourette syndrome	0.00805	0.0243	CbGeAlD
Ondansetron—KCNH2—midbrain—Gilles de la Tourette syndrome	0.00786	0.0238	CbGeAlD
Ondansetron—OPRM1—brain—Gilles de la Tourette syndrome	0.00752	0.0227	CbGeAlD
Ondansetron—HTR1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00749	0.0112	CbGpPWpGaD
Ondansetron—HTR1B—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00741	0.0111	CbGpPWpGaD
Ondansetron—SLC47A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00741	0.0111	CbGpPWpGaD
Ondansetron—HTR1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00728	0.0109	CbGpPWpGaD
Ondansetron—HTR1A—nervous system—Gilles de la Tourette syndrome	0.00726	0.0219	CbGeAlD
Ondansetron—HTR1A—central nervous system—Gilles de la Tourette syndrome	0.00699	0.0211	CbGeAlD
Ondansetron—HTR1B—brain—Gilles de la Tourette syndrome	0.00688	0.0208	CbGeAlD
Ondansetron—HTR1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00678	0.0101	CbGpPWpGaD
Ondansetron—KCNH2—nervous system—Gilles de la Tourette syndrome	0.00646	0.0195	CbGeAlD
Ondansetron—HTR1B—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00623	0.00932	CbGpPWpGaD
Ondansetron—KCNH2—central nervous system—Gilles de la Tourette syndrome	0.00622	0.0188	CbGeAlD
Ondansetron—HTR1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.00565	0.00844	CbGpPWpGaD
Ondansetron—HTR1A—brain—Gilles de la Tourette syndrome	0.00555	0.0168	CbGeAlD
Ondansetron—HTR4—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00541	0.00808	CbGpPWpGaD
Ondansetron—HTR4—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00525	0.00785	CbGpPWpGaD
Ondansetron—CYP2E1—nervous system—Gilles de la Tourette syndrome	0.00498	0.015	CbGeAlD
Ondansetron—KCNH2—brain—Gilles de la Tourette syndrome	0.00494	0.0149	CbGeAlD
Ondansetron—HTR4—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00489	0.00731	CbGpPWpGaD
Ondansetron—CYP2E1—central nervous system—Gilles de la Tourette syndrome	0.00479	0.0145	CbGeAlD
Ondansetron—SLC47A1—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.00478	0.00714	CbGpPWpGaD
Ondansetron—HTR1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.00475	0.0071	CbGpPWpGaD
Ondansetron—HTR4—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00463	0.00692	CbGpPWpGaD
Ondansetron—HTR4—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.0045	0.00672	CbGpPWpGaD
Ondansetron—HTR4—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00419	0.00626	CbGpPWpGaD
Ondansetron—CYP3A4—nervous system—Gilles de la Tourette syndrome	0.00401	0.0121	CbGeAlD
Ondansetron—CYP2D6—nervous system—Gilles de la Tourette syndrome	0.00394	0.0119	CbGeAlD
Ondansetron—CYP3A4—central nervous system—Gilles de la Tourette syndrome	0.00386	0.0116	CbGeAlD
Ondansetron—CYP2E1—brain—Gilles de la Tourette syndrome	0.00381	0.0115	CbGeAlD
Ondansetron—CYP2D6—central nervous system—Gilles de la Tourette syndrome	0.0038	0.0115	CbGeAlD
Ondansetron—SLC47A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00377	0.00563	CbGpPWpGaD
Ondansetron—HTR3A—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00375	0.0056	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00353	0.00527	CbGpPWpGaD
Ondansetron—HTR4—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00342	0.00512	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00342	0.00512	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00319	0.00477	CbGpPWpGaD
Ondansetron—CYP2D6—brain—Gilles de la Tourette syndrome	0.00301	0.0091	CbGeAlD
Ondansetron—HTR4—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00293	0.00439	CbGpPWpGaD
Ondansetron—KCNH2—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.0026	0.00388	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00243	0.00364	CbGpPWpGaD
Ondansetron—SLC47A1—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00243	0.00363	CbGpPWpGaD
Ondansetron—KCNH2—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.00237	0.00354	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00236	0.00353	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00226	0.00338	CbGpPWpGaD
Ondansetron—HTR4—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.00223	0.00334	CbGpPWpGaD
Ondansetron—HTR1B—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.0022	0.00329	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00219	0.00328	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00215	0.00321	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.00209	0.00312	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00204	0.00305	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00199	0.00298	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.00199	0.00298	CbGpPWpGaD
Ondansetron—OPRM1—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00194	0.0029	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00194	0.00289	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00194	0.00289	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.00194	0.00289	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00188	0.00281	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.00185	0.00277	CbGpPWpGaD
Ondansetron—HTR3A—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.00184	0.00275	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.00181	0.00271	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.0018	0.00269	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.0018	0.00269	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.0018	0.00269	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.00176	0.00263	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00175	0.00262	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.00172	0.00257	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00171	0.00255	CbGpPWpGaD
Ondansetron—HTR1A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.00168	0.00251	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.00167	0.0025	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00166	0.00248	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.00164	0.00245	CbGpPWpGaD
Ondansetron—HTR1A—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00163	0.00244	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.00156	0.00233	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00154	0.00231	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.00147	0.0022	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00147	0.0022	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.00143	0.00214	CbGpPWpGaD
Ondansetron—HTR1B—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00143	0.00214	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00143	0.00214	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00133	0.00199	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00133	0.00199	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.0013	0.00194	CbGpPWpGaD
Ondansetron—OPRM1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00126	0.00189	CbGpPWpGaD
Ondansetron—HTR4—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.00126	0.00189	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00126	0.00189	CbGpPWpGaD
Ondansetron—HTR1B—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00123	0.00183	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00118	0.00176	CbGpPWpGaD
Ondansetron—HTR4—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.00115	0.00171	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00112	0.00168	CbGpPWpGaD
Ondansetron—HTR1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.00109	0.00163	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.00109	0.00163	CbGpPWpGaD
Ondansetron—OPRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00108	0.00162	CbGpPWpGaD
Ondansetron—CYP3A7—Metabolism—HDC—Gilles de la Tourette syndrome	0.00107	0.0016	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00107	0.0016	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00104	0.00155	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00102	0.00152	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000967	0.00145	CbGpPWpGaD
Ondansetron—HTR1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000934	0.0014	CbGpPWpGaD
Ondansetron—HTR1B—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000933	0.0014	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000833	0.00124	CbGpPWpGaD
Ondansetron—OPRM1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000824	0.00123	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000808	0.00121	CbGpPWpGaD
Ondansetron—CYP2E1—Metabolism—HDC—Gilles de la Tourette syndrome	0.000777	0.00116	CbGpPWpGaD
Ondansetron—CYP3A5—Metabolism—HDC—Gilles de la Tourette syndrome	0.000775	0.00116	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000756	0.00113	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000753	0.00113	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000735	0.0011	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000734	0.0011	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000713	0.00107	CbGpPWpGaD
Ondansetron—HTR1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000711	0.00106	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000684	0.00102	CbGpPWpGaD
Ondansetron—HTR4—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000677	0.00101	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000667	0.000998	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000665	0.000994	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000648	0.000969	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.000634	0.000948	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	0.000616	0.000921	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000604	0.000902	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	0.000576	0.000861	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	0.000574	0.000858	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	0.000559	0.000836	CbGpPWpGaD
Ondansetron—CYP2D6—Metabolism—HDC—Gilles de la Tourette syndrome	0.000551	0.000824	CbGpPWpGaD
Ondansetron—CYP2C9—Metabolism—HDC—Gilles de la Tourette syndrome	0.000547	0.000817	CbGpPWpGaD
Ondansetron—HTR1B—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000527	0.000789	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	0.000521	0.000779	CbGpPWpGaD
Ondansetron—HTR1B—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000479	0.000716	CbGpPWpGaD
Ondansetron—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	0.000467	0.000698	CbGpPWpGaD
Ondansetron—OPRM1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000466	0.000696	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000447	0.000668	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000434	0.000648	CbGpPWpGaD
Ondansetron—OPRM1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000423	0.000632	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000404	0.000604	CbGpPWpGaD
Ondansetron—HTR1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	0.000402	0.000601	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.000394	0.000589	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.000383	0.000572	CbGpPWpGaD
Ondansetron—HTR1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	0.000365	0.000545	CbGpPWpGaD
Ondansetron—CYP3A4—Metabolism—HDC—Gilles de la Tourette syndrome	0.00036	0.000539	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000357	0.000533	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	0.00034	0.000509	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	0.00033	0.000494	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	0.000308	0.00046	CbGpPWpGaD
Ondansetron—HTR1B—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000283	0.000423	CbGpPWpGaD
Ondansetron—OPRM1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.00025	0.000373	CbGpPWpGaD
Ondansetron—HTR1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	0.000216	0.000322	CbGpPWpGaD
